http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2691630-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_859cdfebbc1eb9c8ff914d39fa3ef9bc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 1993-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_359e03715f92bbb48ee59264b0c554ba |
| publicationDate | 1993-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2691630-A1 |
| titleOfInvention | Pharmaceutical composition, in particular for oral administration, containing, as active ingredient, a selective 5HT1 receptor agonist. |
| abstract | The invention relates to a pharmaceutical composition, in particular for oral administration, containing as an active ingredient a selective agonist of 5HT1-type receptors. In particular, the invention relates to a non-effervescent anhydrous pharmaceutical composition, for dissolution in an aqueous medium prior to oral administration, which comprises a compound which acts as a 5HT1 receptor agonist or a physiologically acceptable salt or solvate thereof. ci as an active ingredient, this composition being substantially free of magnesium stearate. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018510131-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9744062-A1 |
| priorityDate | 1992-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.